Evidence map›Paper›PMID 35978340›Full record

ArticleRadiation oncology (London, England)2022

Identifying patients with malignant spinal cord compression (MSCC) near end of life who can benefit from palliative radiotherapy.

Dirk Rades, Barbara Segedin, Steven E Schild, Darejan Lomidze, Theo Veninga, Jon Cacicedo

Abstract read
In one paragraph

Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dirk RadesDepartment of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. dirk.rades@uksh.de.
Barbara SegedinDepartment of Radiotherapy, Institute of Oncology Ljubljana and University of Ljubljana, Ljubljana, Slovenia.
Steven E SchildDepartment of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA.
Darejan LomidzeRadiation Oncology Department, Ingorokva High Medical Technology University Clinic and Tbilisi State Medical Univiversity, Tbilisi, Georgia.
Theo VeningaDepartment of Radiotherapy, Dr. Bernard Verbeeten Institute, Tilburg, The Netherlands.
Jon CacicedoDepartment of Radiation Oncology, Biocruces Bizkaia Health Research Institute and Cruces University Hospital, Barakaldo, Vizcaya, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA previous score predicted death ≤ 2 months following radiotherapy for MSCC. For patients with a high probability of early death, best supportive care was recommended. However, some of these patients may benefit from radiotherapy regarding preservation or improvement of motor function. To identify these patients, an additional score was developed.

methodsPre-treatment factors plus radiotherapy regimen were retrospectively evaluated for successful treatment (improved motor function or remaining ambulatory without aid) and post-treatment ambulatory status in 545 patients who died ≤ 2 months. Factors included age, interval from tumor diagnosis until MSCC, visceral metastases, further bone metastases, primary tumor type, sex, time developing motor deficits, pre-treatment ambulatory status, and number of affected vertebrae. Factors significant on both multivariable analyses were included in the score (worse outcomes 0 points, better outcomes 1 point).

resultsOn multivariable analyses, myeloma/lymphoma, time developing motor deficits > 14 days, and pre-treatment ambulatory status were significantly associated with both successful treatment and ambulatory status, affection of 1-2 vertebrae with successful treatment only. On univariable analyses, 1 × 8 and 5 × 4 Gy were not inferior to 5 × 5 Gy and longer-course regimens. Considering the three factors significant for both endpoints, three groups were designed (0, 1, 2-3 points) with treatment success rates of 4%, 15% and 39%, respectively (p < 0.0001), and post-treatment ambulatory rates of 4%, 43% and 86%, respectively (p < 0.0001).

conclusionThis score helps identify patients with MSCC who appear to benefit from palliative radiotherapy in terms of improved motor function or remaining ambulatory in spite of being near end of life.

Indexed as

Spinal Cord CompressionSpinal Cord NeoplasmsSpinal NeoplasmsDeathHumansPrognosisRetrospective StudiesEnd of lifeFunctional outcomesMetastatic spinal cord compressionPalliative radiotherapyPrognostic score

Identifiers

PMID35978340
PMCPMC9387005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.